Andrew Rankine

シニア・アソシエート 


  • Overview

    Andrew is a specialist in intellectual property disputes.  His practice focuses on the life sciences.

    Andrew has particular expertise handling complex patent disputes for global leaders in the pharmaceuticals, biotechnology and medical device industries.  He regularly acts in proceedings before the Federal Court of Australia and High Court of Australia, including applications for urgent interlocutory relief, for clients including Sanofi, Wyeth, Novozymes, ResMed, Cochlear, Samsung Bioepis, Mylan, Actavis and Sun Pharmaceuticals.

    When acting for clients in the life sciences sector, Andrew draws upon his expertise as a qualified medical practitioner and biomedical scientist.  Prior to studying law, Andrew worked in diagnostic pathology and undertook research in cancer biology and immunology.

    Andrew regularly advises clients in the life sciences sector on IP and related regulatory issues.  He has expertise in Australia’s regulatory regime for therapeutic goods and the Pharmaceutical Benefits Scheme.  Andrew has advised the Australian Government on reforms to the PBS and on the regulation of advertisements for therapeutic goods.  He also advises on IP portfolio management, freedom to operate, patent validity, patent term extensions and related matters.

    In addition to his life sciences practice, Andrew handles complex IP disputes for multi-nationals in the electronics, ITC, engineering, finance and resources sectors, including Siemens, BASF, Petroleum Geo-Services and Research Affiliates.  He regularly acts in proceedings before the Australian Patent Office, including patent oppositions and contested amendment applications.

    Many of the disputes on which Andrew acts are multi-jurisdictional and he is experienced in working with counsel across jurisdictions to ensure a seamlessly integrated approach.

    Andrew’s contentious IP experience extends to trade secrets, copyright, designs, trade mark, passing off and IP licensing disputes.

    Andrew is admitted to practice in the Supreme Court of New South Wales and the High Court of Australia.  He is listed in leading directories including Best Lawyers in Australia (Life Sciences Practice) and Doyle’s Guide (Contentions Intellectual Property).

    Qualifications

    • Bachelor of Science, Medicine & Surgery (Honours 1), University of New South Wales
    • Bachelor of Laws (Honours 1), University of Sydney
    • Master of Laws, University of Melbourne

    Professional Affiliations

    • Intellectual Property Society of Australia and New Zealand (IPSANZ)
    • American Intellectual Property Law Association (AIPLA)
    • International Association for the Protection of Intellectual Property (AIPPI)
  • Services
  • Technical & Industry Expertise
  • Publications
  • Andrew is a specialist in intellectual property disputes.  His practice focuses on the life sciences.

    Andrew has particular expertise handling complex patent disputes for global leaders in the pharmaceuticals, biotechnology and medical device industries.  He regularly acts in proceedings before the Federal Court of Australia and High Court of Australia, including applications for urgent interlocutory relief, for clients including Sanofi, Wyeth, Novozymes, ResMed, Cochlear, Samsung Bioepis, Mylan, Actavis and Sun Pharmaceuticals.

    When acting for clients in the life sciences sector, Andrew draws upon his expertise as a qualified medical practitioner and biomedical scientist.  Prior to studying law, Andrew worked in diagnostic pathology and undertook research in cancer biology and immunology.

    Andrew regularly advises clients in the life sciences sector on IP and related regulatory issues.  He has expertise in Australia’s regulatory regime for therapeutic goods and the Pharmaceutical Benefits Scheme.  Andrew has advised the Australian Government on reforms to the PBS and on the regulation of advertisements for therapeutic goods.  He also advises on IP portfolio management, freedom to operate, patent validity, patent term extensions and related matters.

    In addition to his life sciences practice, Andrew handles complex IP disputes for multi-nationals in the electronics, ITC, engineering, finance and resources sectors, including Siemens, BASF, Petroleum Geo-Services and Research Affiliates.  He regularly acts in proceedings before the Australian Patent Office, including patent oppositions and contested amendment applications.

    Many of the disputes on which Andrew acts are multi-jurisdictional and he is experienced in working with counsel across jurisdictions to ensure a seamlessly integrated approach.

    Andrew’s contentious IP experience extends to trade secrets, copyright, designs, trade mark, passing off and IP licensing disputes.

    Andrew is admitted to practice in the Supreme Court of New South Wales and the High Court of Australia.  He is listed in leading directories including Best Lawyers in Australia (Life Sciences Practice) and Doyle’s Guide (Contentions Intellectual Property).

    Qualifications

    • Bachelor of Science, Medicine & Surgery (Honours 1), University of New South Wales
    • Bachelor of Laws (Honours 1), University of Sydney
    • Master of Laws, University of Melbourne

    Professional Affiliations

    • Intellectual Property Society of Australia and New Zealand (IPSANZ)
    • American Intellectual Property Law Association (AIPLA)
    • International Association for the Protection of Intellectual Property (AIPPI)